Previous cytomegalovirus infection and the risk of restenosis after a strategy of provisional stenting  by Mueller, Christian et al.
JACC March 6,2002 ABSTRACTS - ACCIS2002 (Angiography & interventional Cardiology) 31A 
visual loss (1%) and 1 patient (0.5%) had hyperperiusion syndrome. The 2 (2%) non- 
stroke related deaths were from cardio-pulmonary events; the sole (0.5%) neurological 
death was due to intracranial hemorrhage. 
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Conclusion: 1) Carotid stenting using neumprotection devices is feasible. 2) The proce- 
dural related embolic comolications was 3.4% (minor strokes + retinal emboli) 3) There 
were no major strokes and 1 fatal intracranial hemorrhage. 
812-5 Angiographic and Pathologic Studies of Late Vascular 
Responses to Successful Carotid Artery Stenting 
wOdashiro, Hiroyoshi Yokoi, Katsumi Inoue, Takeshi Kimura, Hideyuki Nosaka, 
Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu, Japan. 
Background: There was linle angiographic follow-up data and pathologic studies for 
patients receiving stents at extracranial carotid arteries. The purpose of this study was to 
assess the long-ferm efficacy of carotid artery stenting (CAS) angiographically and histo- 
pathologically. 
Methods: Out of 29 patients with 36 lesions undergoing 6 months follow-up angiogrephy, 
1-2 years follow-up angiography was available in 14 patients with 19 lesions. Quantita- 
tive angiographic analysis was pedoned. Minimal luminal diameter(MLD), interpolated 
referense diameter and % diameter stenosis were measured. Stent sites were divided 
into 10 segments. At each segments, minimal diameter and mean diameter were mea- 
sured. Histopathologic examination was performed in patients undergoing antemortem 
GAS. Temporal Ganges in histologic pattern between 6 months and 3 years were exam- 
ined. 
Results: At stenotic segments greater than 50% before CAS, neointimal hyperplasia 
became greater than other segments at 6 months. Follow-up angiography of 19 lesions 
at 6 months and 1-2 years revealed a decrease in MLD from 4.41&0.55mm immediately 
after stent implantation to 3.45i0.39 mm at 6 months, but no further decrease in diams- 
tar after 6 months. Late improvement in tuminal diameter was observed after 6 months. 
(3.45*0.39mm at 6 months and 3.76eO.3 mm at l-2 years : P=O.O15). Micrographs of the 
stented segment of the 6 months after CAS revealed significant proliferation of smooth 
muscle cells(SMCs) and abundunt deposition of extracellular matrix substance chiefly 
composed of proteoglycans on the intimal side. In contrast, aftre 3 years. neointima was 
primarily composed of dense fibrous collagenous tissue and atrophic SMCs. Lipid core in 
the atheroma was covered with stable neolntima. 
Conclusion: Angiographic outcomes up to 2 years after CAS were favorable. Late 
improvement of neointimal hyperplasia appears to occur after 6 months. Temporal 
changes in histologic panem provide a pathologic backgound for the long-term efficacy 
of CAS. 
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1102-l Previous Cytomegalovirus Infection and the Risk of 
Restenosis After a Strategy of Provisional Stenting 
vMueller. John M. Hodgson, Heinz J. Buenner, Stephan Marsh. Helmut 
Aoskamm, Hen-Zentrum, Bad Kro.?ingen. Gemrany, University Hospital, Base/, 
Switzerland. 
Background: Previous studies have shown that prior infection with cytomegalovirus 
(CMV) is a predictor of restenosis after atherectomy. 
Methods: We prospectively studied 76 consecutive patients scheduled for 6-months fol- 
low-up coronary angiography as par? of the SIPS study. Anti-CMV IgG and IgM antibod- 
ies were measured to determine whether previous exposure to CMV increased the risk of 
restenosis after a strategy of provisional stenting. In 76 patients (99%), the coronary 
angiograms before, directly after and B-months after the intervention could be analyzed 
quantitatively. 
Results: Anti-CMV IgG positive and anti-CMV IgG negative patients had similar minimal 
lumen diameter (MLD) in the target vessel before and directly after the intervention. After 
six months, however, the MLD was significantly smaller in CM&positive as compared to 
CMV-negative patients (1.57eO.62 mm versus 2.00i0.63 mm. ~~0.03). Net lumen gain at 
6 months was significantly lower in CMV-positive patients (0.69*0.79 mm versus 
1.30t0.67 mm, p<O.O4), and the rate of clinically significant restenosis was significantly 
higher (31% versus 7%, p<O.O2). In a mu/tivariate logistic regression model, CMV-serop- 
ositivity was an independent predictor of restenosis (odds ratio 5.7 (95%CI 1.2-30.3, 
p=0.04)). 
Conclusion: CMV-seropositivity is an independent predictor of restenosis following core- 
nary intervention. 
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1102-2 Role of Chlamydia Pneumoniae for Restenosls After 
Percutaneous Coronary Intervention: The SWICA 
(Swiss Cardiovascular Center Chlamydia) Trial 
mMaier. Marco Corti, Thomas Orsucci, Stephan Windecker, Bernhard Meiet, Otto 
M. Hess, Cardiology, University Hospital Zurich, Zurich, Switzerland, Cafdio/og~ Swiss 
Cardiovascular Center Bern, Bern, Switzerland. 
Background: Recently, a reduction of restenosis rate after stenting has been reported in 
patients with high Chlamydia pneumoniae titers treated with the macrolide antibiotic 
roxithromycin. The purpose of the present study (SWICA Trial) was to evaluate the effect 
of clarithromycin for prevention of coronary restenosis in patients with routine percutans- 
ous coronary intervention (PTCA with and without stenting) and concomitant assessment 
of antibody titers. 
Methods and Results: In a randomized, double-blind, placebo-controlled single center 
pilot study 66 patients with coronary artsly disease undergoing PTCA were randomized 
to receive either standard therapy (placebo group, n=42) or treatment with 2x250 mg 
clarithromycin for six weeks (treatment group, n=44). Primary endpoint was angiographic 
restenosis and secondary endpoint major adverse cardiac evsnts (MACE). The patients 
underwent follow-up angiography after 3 months. Stent implantation was performed in 
67% of all cases. Antibody tiers were taken at randomization and at the end of the fol- 
low-up period. Age, gender, body mass index, history of myocardial infarction as well as 
cardiovascular risk factors were evenly distributed in the two groups. Diameter stenosis 
was similar at follow-up (33% vs. 34%, ns) in both groups. Restenosis rate (=-504/o diame- 
ter stenosis) was 23% in the treatment and 21% (ns) in the placebo group, respectively. 
MACE occurred in 16% and 29% (ns). respectively. Antibody titers for Chlamydia pneu- 
moniae, Cytomegalovirus and Helicobacter pylori were similar in the two groups at ran- 
domization and at follow-up without any correlation to restenosis rate. Only Helicobactsr 
pylori titers decreased significantly after antibiotic therapy. 
Conclusions: Restenosis rate after PTCA is not influenced by clarithromycin treatment. 
Ssropositivity for Chlamydia pneumoniae, Cytomegalovirus and Helicobacter pylori was 
not associated with an increased risk of restenosis after percutaneous coronary interven- 
tions. Thus, a major pathogenic role of Chlamydia pneumoniae for restenosis after per- 
cutaneous coronary intervention appears unlikely. 
1102-21 Preprocedural Levels of Acute Phase Reactants Predict 
an Aggressive Clinical Pattern of Restenosis Following 
Coronary Angioplasty 
mBuffon, Giovanna Liuzzo, Marco Centola, Laura Canale, Patrizio Pasqualeni, 
Antonio G. Rebuzzi, Luigi M. Biasucci, Catholic Universify. Rome, /ta/x A.Fa.R., 
Ospedale Fetebenefratelli-/so/a Tiberina, Rome, /ta/y 
Background: In a subset of patients undergoing coronaty angioplasty (PTCA), resteno- 
sis is not a benign clinical event but it is associated with recurrence of severe unstable 
angina (UA), myocardial infarction (Ml) or cardiac death (CD). Acute phase reactants are 
powerful predictors of angiographic restenosis following PTCA, but it is unclear whether 
they can also identify patients with acute coronary events at long term follow-up. 
Methods: We investigated whether pm-procedural plasma levels of C-reactive protein 
(CRP) and serum amyloid-A protein (SAA) might predict the clinical severity of restenosis 
at one year follow-up in a group of 111 consecutive patients undergoing successful sin- 
gle-lesion PTCA. 
Results: At f year, clinical restenosis, defined as recurrence of symptoms and/or posi- 
tive exercise test and confirmed by the angiographic evidence of > 50% stenosis at the 
site of PTCA, occurred in 51 patients (46%). Among them, 26 patients (25%) had a more 
aggressive panern of testenosis requiring urgent hospital admission because of severe 
UA (23 patients, 21%) or MI (5 patients, 5%). Recurrence of VA or Ml was 46% and 50% 
in patients with elevated levels of CRP (> 3 mg/L) and SAA (> 5 mg/L), and 2% 
(P-zO.001) and 6% (PcO.001) respectively in patients with normal levels. Among several 
clinical, angiographic and procedural variables analyzed by Cox proportional hazards 
regression model, CRP was the most powerful independent predictor of an aggressive 
pattern of restenosis (RR=14.3, CI=l.6-111.7, P=O.Oll). 
Conclusions: Our data demonstrate that elevated pm-procedural levels of acute phase 
reactants predict a more aggressive clinical pattern of restenosis, requiring emergeni 
hospitalization. Close post-PICA surveillance is necessary in these patients. 
